SEC Form 4Coverage since Jun 15, 2026
$TARS insider trading
Over the last 12 months, Tarsus Pharmaceuticals insiders reported no purchases and 4 sales totaling $2.5M across SEC Form 4 filings. 75% of the activity was filed under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $2.5M 4 events
- Events · 12m
- 4 Form 4 filings, grouped
- Insiders · 12m
- 4 distinct reporters
- 10b5-1 share
- 75% pre-arranged plans
Side
Price · $TARS · 12Mvia TradingView
Top insiders · 12m
Goodrich Katherine—1× · $183K
Azamian Bobak R.President/CEO and Board Chair1× · $615K
LINK WILLIAM J PHD—1× · $776K
Farrow Jeffrey SSee Remarks1× · $877K
All insider trades
4 events
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Jun 17, 2026 | Azamian Bobak R.President/CEO and Board Chair · O·D | ▼ Sale | 10,000 | $61.55 | $615K | -1.2% | plan · 2 tranches · indirect |
| Jun 16, 2026 | Farrow Jeffrey SSee Remarks · O | ▼ Sale | 14,396 | $60.95 | $877K | -20.2% | — |
| Jun 15, 2026 | Goodrich KatherineD | ▼ Sale | 2,954 | $62.08 | $183K | -57% | plan |
| Jun 15, 2026 | LINK WILLIAM J PHDD | ▼ Sale | 12,500 | $62.12 | $776K | -10.5% | plan · 2 tranches |
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $TARS feed.